In this issue of Blood, Newberry et al provide evidence that clonal evolution in patients with myelofibrosis (MF) who are receiving therapy with ruxolitinib correlates with discontinuation of treatment, mainly because of loss of response or progression, and also predicts shorter survival thereafter.1
Traffic lights for ruxolitinib / Vannucchi, Alessandro M.; Guglielmelli, Paola. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 130:(2017), pp. 1075-1077. [10.1182/blood-2017-07-795880]
Traffic lights for ruxolitinib
Vannucchi, Alessandro M.
;Guglielmelli, Paola
2017
Abstract
In this issue of Blood, Newberry et al provide evidence that clonal evolution in patients with myelofibrosis (MF) who are receiving therapy with ruxolitinib correlates with discontinuation of treatment, mainly because of loss of response or progression, and also predicts shorter survival thereafter.1
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
10.1182@blood-2017-07-795880_AMV.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
584.76 kB
Formato
Adobe PDF
|
584.76 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
